VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger ...(actorsis contained in VaxGen's Annual Re...),Health

Date:3/20/2008

actors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen and Raven undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Additional Information and Where to Find It

VaxGen has filed a registration statement on Form S-4, and a related proxy statement/prospectus, in connection with the merger. Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy/prospectus (including any amendments or supplements to the proxy statement/prospectus) because they contain important information about the merger transaction. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting VaxGen Investor Relations at the email address: ir@vaxgen.com.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

VaxGen, Raven and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of VaxGen in connection with the merger
'/>"/>

SOURCE VaxGen Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. USAID Provides Additional Wildfire Assistance to Greece
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy